missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human NOLC1 (aa 10-81) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (84%), Rat (84%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-83366 (PA5-83366. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Related to nucleologenesis, may play a role in the maintenance of the fundamental structure of the fibrillar center and dense fibrillar component in the nucleolus. It has intrinsic GTPase and ATPase activities. May play an important role in transcription catalyzed by RNA polymerase I.
Specifications
Specifications
| Accession Number | Q14978 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9221 |
| Name | Human NOLC1 (aa 10-81) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 140 kDa nucleolar phosphoprotein; HCV NS5A trans-regulated protein 13; HCV NS5A-transactivated protein 13; Hepatitis C virus NS5A-transactivated protein 13; KIAA0035; NOLC1; nolc1.L; nopp130; nopp140; NS5ATP13; Nucleolar 130 kDa protein; nucleolar and coiled-body phosphoprotein 1; nucleolar and coiled-body phosphoprotein 1 L homeolog; nucleolar and coiled-body phosphprotein 1; nucleolar phosphoprotein; nucleolar phosphoprotein 140; nucleolar phosphoprotein p130; nucleolar protein p130; P130; XELAEV_18034881mg; xNopp180 |
| Common Name | NOLC1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction